Niraparib (MK-4827) tosylate

For research use only. Not for use in humans.

目录号：S7625 别名： Niraparib tosylate, MK 4827 tosylate, ZEJULA 中文名称：尼拉帕尼甲苯磺酸盐

Niraparib (MK-4827) tosylate Chemical Structure

CAS No. 1038915-73-9

Niraparib tosylate (MK-4827, ZEJULA) 是PARP1/PARP2的选择性抑制剂，IC50分别为3.8 nM和2.1 nM。Niraparib可增加PARP-DNA复合体的形成，并导致DNA损伤、凋亡和细胞死亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1449.63	现货
5mg	RMB 959.15	现货
25mg	RMB 3251.76	现货
100mg	RMB 8165.6	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Niraparib (MK-4827) tosylate发表文献29篇：

Sci Transl Med, 2021, 13(592)eabc7211

PubMed: 33952676 ( click the link to review the publication )

Sci Adv, 2021, 7(21)eabf0197

PubMed: 34020950 ( click the link to review the publication )

Cell Rep, 2021, 34(2):108625

PubMed: 33440161 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):97

PubMed: 34315482 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):323

PubMed: 34656146 ( click the link to review the publication )

Cancers (Basel), 2021, 13(17)4405

PubMed: 34503215 ( click the link to review the publication )

Gynecol Oncol, 2021, S0090-8258(21)00325-5

PubMed: 33867143 ( click the link to review the publication )

J Pharmacol Exp Ther, 2021, 377(3):385-397

PubMed: 33820831 ( click the link to review the publication )

Genes (Basel), 2021, 12(6)849

PubMed: 34073147 ( click the link to review the publication )

Exp Cell Res, 2021, 403(2):112614

PubMed: 33905671 ( click the link to review the publication )

Nat Commun, 2021, 12(1):736

PubMed: 33531508 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2573

PubMed: 32444794 ( click the link to review the publication )

Cell Rep, 2020, 31(10):107745

PubMed: 32521270 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0818

PubMed: 33158843 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(7):1004-1017

PubMed: 32238439 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2585

PubMed: 32066817 ( click the link to review the publication )

Head Neck, 2020, 10.1002/hed.26155

PubMed: 32323895 ( click the link to review the publication )

Oncotarget, 2020, 11(23):2141-2159

PubMed: 32577161 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):775

PubMed: 32811446 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1270-1285

PubMed: 31351877 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(12):1223-1231

PubMed: 31659317 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):525-533

PubMed: 29405820 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

SLAS Discov, 2018, 23(6):545-553

PubMed: 29676938 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5576-5590

PubMed: 28790064 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Chem Biol Drug Des, 2016, 87(3):478-82

PubMed: 26518726 ( click the link to review the publication )

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述

靶点

PARP2 ^[3] (Cell-free assay)	PARP1 ^[3] (Cell-free assay)
2.1 nM	3.8 nM

体外研究

微摩尔级浓度的niraparib使来自于肺癌、乳腺癌以及前列腺癌的肿瘤细胞对放射线敏感（不依赖于它们的p53状态），而对来自于正常组织的细胞没有此作用。Niraparib同样还可以使肿瘤细胞对过氧化氢敏感、在DNA复制时，将过氧化氢诱导的单链断裂转变为双链断裂^[5]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HeLa	NUL2bmJxTnWwY4Tpc44h[XO\|YYm=			M1LUbGlvcGmkaYTpc44hd2ZiUFHSVEBqdiCqeXTyc4dmdiCyZYLvfIll\S2rbnT1Z4VlKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDEUmEu\GGvYXflMYlv\HWlZXSgVGFTgWyjdHnvckwhTUN3MDC9JFAvODB2IN88UU4>	NET1XVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi3N\|k5OSd-MUm4O\|M6QDF:L3G+
MDA-MB-436	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVXjWVFiPiCmYYnz	M2jFcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTR\|NjDj[YxteyCneIDy[ZN{cW6pIFLSR2EyKDV\|OU[gL{AyTz6DIH31eIFvfCCjZoTldkA3KGSjeYOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDDR\|UxKD1iMD6wNVgh\|ryPLh?=	NF\Ze4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi3N\|k5OSd-MUm4O\|M6QDF:L3G+
HeLa	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MV63JIRigXN?	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EyKGSnZnnjbYVvfCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFch\GG7czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFPDOVAhRSByLkCzN{DPxE1w	M1T6VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEezPVgyLz5zOUi3N\|k5OTxxYU6=
HeLa	M1TqbGZ2dmO2aX;uJIF{e2G7			MVrJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHmmcn;n[Y4heGW{b4jp[IUucW6mdXPl[EBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25iRF7BMYRidWGpZT3pcoR2[2WmIGDBVplt[XSrb36sJGVEQTBiPTCwMlA1PSEQvF2u	M374UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEezPVgyLz5zOUi3N\|k5OTxxYU6=
Capan1	M2DS[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2nSblE{KGSjeYO=	MlraRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFYYDhclEh[2WubIOg[ZhxemW\|c3nu[{BDWkODMjC2NVc1\GWuVDDteZRifGmxbjDhcoQhdG:\|czDv[kB4cWymLYT5dIUh[WyuZXzlJIFnfGW{IEGzJIRigXNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCFQ{WwJF0hOC5yOTFOwG0v	NVLQV3VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4O\|M6QDFpPkG5PFc{QThzPD;hQi=>
HeLa	Ml\mRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmLkO{Bl[Xm\|	NYH6Ro5YSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKUQ1GxJIFnfGW{IEeg[IF6eyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEOFNUCgQUAxNjh4IN88UU4>	NVjjOWl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4O\|M6QDFpPkG5PFc{QThzPD;hQi=>
MDA-MB-436	NXfuV5FxSW62aYT1cY9zKGG\|c3H5	M3jFVVUxKG2pL3vn	M{DLdVM{KGSjeYO=	MVPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuPDN4IHPlcIx{KGW6cILld5NqdmdiQmLDRVEhPTN7NjCrJFFIRkFibYX0ZY51KHinbn;ndoFnfGWmIHnuJGNFOSCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBz\We{ZYPzbY9vKGG2IEWwJI1oN2upLDDwc{BjcWRiZn;yJFM{KGSjeYO=	NUPpUllyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4O\|M6QDFpPkG5PFc{QThzPD;hQi=>
MDA-MB-436	MoKyRY51cXS3bX;yJIF{e2G7	NX3YN3JROTByIH3nM4to	MXezN{Bl[Xm\|	M4C0U2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12M{[gZ4VtdHNiZYjwdoV{e2mwZzDCVmNCOSB3M{m2JEshOUd-QTDteZRidnRieHXuc4dz[W[2ZXSgbY4hS0RzIH3veZNmKGG\|c3Xzd4VlKGG\|IIT1cY9zKHKnZ4Lld5Nqd25iYYSgNVAxKG2pL3vnMEBxdyCzZDDmc5IhOzNiZHH5dy=>	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6N{O5PFEoRjF7OEezPVgyRC:jPh?=
Jurkat	NGjZSpVHfW6ldHnvckBie3OjeR?=		MVe5OkBpenN?	M4T5PGlvcGmkaYTpc44hd2ZiUFHSVFEhcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iClZXzsJJZq[WKrbHn0fUBi\nSncjC5OkBpenNiYomgUXRUKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEGwNEB2VSCxZjD0[Y1wgm:ub33p[IUtKEWFNUCgQUAxNjJizszNMi=>	NGTBdGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFE6QSd-MkO4OVAyQTl:L3G+
Jurkat	MUDGeY5kfGmxbjDhd5NigQ>?		MlzZPVYhcHK\|	NUjmR3VHUW6qaXLpeIlwdiCxZjDQRXJROSCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIHPlcIwhfmmjYnnsbZR6KGGodHXyJFk3KGi{czDifUBOXFNiYYPzZZktKEWFNUCgQUA{OSEQvF2u	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEG5PUc,OjN6NUCxPVk9N2F-
CAPAN-1	NXPBVVJ4TnWwY4Tpc44h[XO\|YYm=			NXr0NGJUUW6qaXLpeIlwdiCxZjDQRXJRKGmwIFLSR2EzNWSnZnnjbYVvfCCqdX3hckBESVCDTj2xJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaInkdo9o\W5icHXyc5hq\GVvaX7keYNm\CCSQWL5cIF1cW:wIHL5JINmdGxvYnHz[YQh[XO\|YYmsJGlEPTBiPTCwMlAxOzVizszNMi=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
HeLa	MXHGeY5kfGmxbjDhd5NigQ>?			Mlr2TY5pcWKrdHnvckBw\iCSQWLQJIlvKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[U1qdmS3Y3XkJHBCWnmuYYTpc44h[nliY3XscE1j[XOnZDDhd5NigSxiRVO1NEA:KDBwMEC0JO69VS5?	NHjL[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
A2780	Ml62SpVv[3Srb36gZZN{[Xl?			MW\Jcohq[mm2aX;uJI9nKFCDUmCgbY4hcHWvYX6gRVI4QDBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[U1qdmS3Y3XkJHBCWnmuYYTpc44h[nliY3XscE1j[XOnZDDhd5NigSxiSVO1NEA:KDBwMEC0JO69VS5?	M3S0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xNFk3Lz5{NUe2NVA6PjxxYU6=
A549	NFvhZ5pEgXSxdH;4bYNqfHliYYPzZZk>		M1XhN\|UhfG9iNzDkZZl{	M2\ndmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMhfHKjboPm[YN1\WRid3n0bEBDWkODMjDzbHJPSSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA2KHSxIEeg[IF6eyCkeTDD[YxtXGm2ZYKtRox2\SCjc4PhfUwhS0N3MDC9JFAvODFzIN88UU4>	NYPac2JDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O\|YyODl4PD;hQi=>
MDA-MB-436	MULDfZRwfG:6aXPpeJkh[XO\|YYm=			M1zDPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N\|Yh[2WubIOgZ4FzenmrbnegRnJESTFibYX0ZY51KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vNCCFQ{WwJF0hOC5yMUig{txONg>?	NG\Be2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
SUM1315MO2	NESycI1EgXSxdH;4bYNqfHliYYPzZZk>		MWOxNkBl[Xm\|	MlzZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3VOOTNzNV3PNkBk\WyuczDjZZJzgWmwZzDCVmNCOSCvdYThcpQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgNVIh\GG7czDifUBE\WyuVHn0[ZIuSmy3ZTDhd5NigSxiQ1O1NEA:KDBwMEKg{txONg>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
DoTc2-4510	M1;FXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoLvOUB1dyB5IHThfZM>	NGDsR\|REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFd1SlMj20OVExKGOnbHzzJINienK7aX7nJGJTS0F{IH31eIFvfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA2KHSxIEeg[IF6eyCkeTDD[YxtXGm2ZYKtRox2\SCjc4PhfUwhS0N3MDC9JFAvODJ\|IN88UU4>	NVv6Z5NnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O\|YyODl4PD;hQi=>
SUM149PT	MnTGR5l1d3SxeHnjbZR6KGG\|c3H5		MmP0OUB1dyB5IHThfZM>	MoS2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3VOOTR7UGSgZ4VtdHNiY3HydplqdmdiQmLDRVEhdXW2YX70JIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEWgeI8hPyCmYYnzJIJ6KEOnbHzUbZRmei2EbIXlJIF{e2G7LDDDR\|UxKD1iMD6wNlQh\|ryPLh?=	Mom2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
HeLa	M{n6NGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1O3N\|UhfG9iNzDkZZl{	MoK5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJTS0FzIIPoVm5CKGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB3IITvJFch\GG7czDifUBE\WyuVHn0[ZIuSmy3ZTDhd5NigSxiQ1O1NEA:KDBwMEO0JO69VS5?	MlrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
HeLa	MmC5SpVv[3Srb36gZZN{[Xl?			MVPJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlMYlv\HWlZXSgVGFTgWyjdHnvckBjgSClZXzsMYJie2WmIHHzd4F6NCCLQ{mwJF0hOC5yNE[g{txONg>?	NECyR5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
CAPAN-1	NHXGN\|dHfW6ldHnvckBie3OjeR?=			NFn6[YtKdmirYnn0bY9vKG:oIGDBVnAhcW5iQmLDRVIu\GWoaXPp[Y51KGi3bXHuJGNCWEGQLUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqeXTyc4dmdiCyZYLvfIll\S2rbnT1Z4VlKFCDUonsZZRqd25iYomgZ4VtdC2kYYPl[EBie3OjeTygTWM6OCB;IECuNFUh\|ryPLh?=	NEjucY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
A2780	NYnoOGNFTnWwY4Tpc44h[XO\|YYm=			M3myOmlvcGmkaYTpc44hd2ZiUFHSVEBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGi7ZILv[4VvKHCncn;4bYRmNWmwZIXj[YQhWEGUeXzheIlwdiCkeTDj[YxtNWKjc3XkJIF{e2G7LDDJR\|kxKD1iMD6wOVIh\|ryPLh?=	MmjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
UWB1.289	NFPKWIpEgXSxdH;4bYNqfHliYYPzZZk>		NHm3Tmk2KHSxIEeg[IF6ew>?	MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVW2IyNjJ6OTDj[YxteyClYYLyfYlv\yCEUlPBNUBufXSjboSgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNTD0c{A4KGSjeYOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFPDOVAhRSByLkC1OkDPxE1w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
Capan1	NEP6[ohEgXSxdH;4bYNqfHliYYPzZZk>			NGDCTYlEgXSxdH;4bYNqfHliYXfhbY5{fCCEUlPBNk1l\W[rY3nlcpQhcHWvYX6gR4Fx[W5zIHPlcIx{NCCFQ{WwJF0hOC5yOTFOwG0v	NFPMeog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
HeLa	MV7DfZRwfG:6aXPpeJkh[XO\|YYm=		NX;tflFzPSC2bzC3JIRigXN?	MmTXR5l1d3SxeHnjbZR6KGGpYXnud5Qhf2muZDD0fZBmKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOUB1dyB5IHThfZMh[nliQ3XscHRqfGW{LVLseYUh[XO\|YYmsJGNEPTBiPTCwMlg2OiEQvF2u	NFrn[oY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
UWB1.289	MlnOR5l1d3SxeHnjbZR6KGG\|c3H5		Mnz6OUB1dyB5IHThfZM>	NGr0TWFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWX0JzLkK4PUBk\WyuczDlfJBz\XO\|aX7nJGJTS0FzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDVidH:gO{Bl[Xm\|IHL5JGNmdGyWaYTldk1DdHWnIHHzd4F6NCCFQ{WwJF0hOC57N{Wg{txONg>?	M1;4cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xNFk3Lz5{NUe2NVA6PjxxYU6=
A549	M3PwZmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3PCdlUhfG9iNzDkZZl{	NYe4TI9[S3m2b4TvfIlkcXS7IHHnZYlve3Rid3ns[EB1gXCnIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPSC2bzC3JIRigXNiYomgR4VtdFSrdHXyMWJtfWViYYPzZZktKEOFNUCgQUAyNjd4IN88UU4>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
BT20	MkjVR5l1d3SxeHnjbZR6KGG\|c3H5		M{XIdVUhfG9iNzDkZZl{	M1L0TWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJVOjBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOUB1dyB5IHThfZMh[nliQ3XscHRqfGW{LVLseYUh[XO\|YYmsJGNEPTBiPTCyMlIh\|ryPLh?=	NYfnc3VYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O\|YyODl4PD;hQi=>
MDA-MB-436	MUPBcpRqfHWvb4KgZZN{[Xl?	MmGxPFAhdWdxa3e=	NWfTfpNjOSC2bzCyJJdm\Wu\|	NEnP[G5CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO2JINmdGy\|IHjhdoJwemmwZzDCVmNCOSCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gbY1ufW6xY3;tdJJwdWm\|ZXSgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgPFAhdWdxa3esJJBwKHGmIH\vdkAyKHSxIEKge4Vmc3N?	MoXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
MDA-MB-436	M3nPbGFvfGm2dX3vdkBie3OjeR?=	M33WVVgxKG2pL3vn	MlnFOEB4\WWtcx?=	MX;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuPDN4IHPlcIx{KGijcnLvdolv\yCEUlPBNUBufXSjboSgfIVvd2e{YX\0[YQhcW5iaX3teY5w[2:vcILvcYl{\WRibX;1d4Uh[XO\|ZYPz[YQh[XNiY3;tdIxmfGViYX7kJJN2e3SjaX7l[EB1fW2xcjDy[Ydz\XO\|aX;uJIF1KDhyIH3nM4toNCCybzDx[EBnd3JiNDD3[YVsew>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
MDA-MB-436	Ml7jRY51cXS3bX;yJIF{e2G7	M3HjS\|UxKG2pL3vn		NUSycHkxSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOkBk\WyuczDoZZJjd3KrbnegRnJESTFibYX0ZY51KHinbn;ndoFnfGWmIHnuJIludXWwb3PvcZBzd22rc3XkJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUxKG2pL3vnMEBxdyCjZH3pcol{fGW{ZXSg[IFqdHl?	MkT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
MDA-MB-436	NWTtZmhMSW62aYT1cY9zKGG\|c3H5	Ml:2PFAhdWdxa3e=	M16wZVMhf2Wna4O=	M4CwcWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12M{[gZ4VtdHNiaHHyZo9zcW6pIFLSR2EyKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDpcY12dm:lb33wdo9ucXOnZDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiC\|aILpcoti\2ViYYSgPFAhdWdxa3esJJBwKHGmIH\vdkA{KHenZXvz	MoXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
Capan1	M4j3OGN6fG:2b4jpZ4l1gSCjc4PhfS=>			MnLGR5l1d3SxeHnjbZR6KGGpYXnud5QhSlKFQUKt[IVncWOrZX70JIh2dWGwIFPhdIFvOSClZXzsd{whTUN3MDC9JFAvPjVizszNMi=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
TC32	M3jR[5FJXFNiYYPzZZk>			NFTLN5hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	NGLi[Yw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NVq0XHVLeUiWUzDhd5NigQ>?			NYXZWHlQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NH65T5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NEX5VoVyUFSVIHHzd4F6			MkPtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NILkVGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NHfO[nRyUFSVIHHzd4F6			MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	M3rSW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NXLDZVVoeUiWUzDhd5NigQ>?			M{PoR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	NHjIR449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NITNW3pyUFSVIHHzd4F6			MmrRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NUPCNpNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	M3:zcZFJXFNiYYPzZZk>			M2jafpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NYTNZXdHeUiWUzDhd5NigQ>?			MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NF[1dmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NGLHcWJyUFSVIHHzd4F6			NIOxR3VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	MnTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	NEfafYZyUFSVIHHzd4F6			MlLIdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	NH;3VWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-PARP /c-caspase 3 / γ-H2AX; PubMed: 29158830 Theranostics Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in W0069 cells.	29158830
Immunofluorescence	Rad51 / Geminin; PubMed: 27614696 Gynecol Oncol Immunofluorescence microscopy of niraparib-treated PDX cells (PH039) and irradiated cells showing RAD51 foci (arrow) within geminin positive cells and lack of RAD51 foci formation in control cells.	27614696

体内研究

MK-4827可以增强放射线对多种人类肿瘤异种移植的作用，无论是在p53野生型或是p53突变体。MK-4827在给药后1小时降低肿瘤中PAR水平并持续效果24小时^[1]。MK-4827体内给药能延长放射线处理后的动物寿命。MK-4827和放射治疗结合，显著提高肿瘤中裂解的caspase-3和γ-H2AX的水平^[4]。

细胞实验：^[2]	- 合并 Cell lines: V-C8细胞 Concentrations: 50 nM Incubation Time: 24 h Method: 用PARP抑制剂MK-4827对中国仓鼠细胞V-C8（BRCA2-negative）进行处理，24小时后，洗涤并将细胞孵育在不含此化合物的培养基中5-7天，直到形成克隆。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 雌性裸鼠(Ncr Nu/Nu) Dosages: 25或50 mg/kg Administration: 口服 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	98 mg/mL (198.94 mM)
	Water	Insoluble
	Ethanol	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Niraparib (MK-4827) tosylate SDF

分子量	492.59
化学式	C₁₉H₂₀N₄O.C₇H₈O₃S
CAS号	1038915-73-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Niraparib tosylate, MK 4827 tosylate, ZEJULA

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

定制您的化合物库

Niraparib (MK-4827) tosylate

客户使用Selleck生产的Niraparib (MK-4827) tosylate发表文献29篇：

产品安全说明书

PARP抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Niraparib (MK-4827) tosylate SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

PARP Signaling Pathway Map

相关PARP产品